BioCentury | Oct 21, 2013
Company News

Osmotica Pharmaceutical management update

...Neurology, Drug delivery Hired: Kenneth Gayron as VP and CFO, formerly VP and treasurer at Sensus...
BioCentury | May 28, 2002
Company News

Tercica Medica Corp. management update

...Calif. Business: Metabolic Hired: John Scarlett as president, CEO and a director, formerly CEO of Sensus...
BioCentury | May 20, 2002
Company News

C Sixty management update

...Sixty Inc. , Houston, Texas Business: Chemistry Hired: Robert Davis as CEO, formerly EVP at Sensus...
BioCentury | Jul 23, 2001
Company News

Hyseq Inc. management update

...Pharmacogenetics Hired: William Bennett as SVP of research, formerly SVP of research and manufacturing at Sensus...
BioCentury | Mar 12, 2001
Company News

Sensus Drug Development Corp., Pharmacia deal

...option to acquire the 81.1 percent of Sensus it did not already own. Last month, Sensus...
...The product has Orphan Drug designation and priority review status. PHA acquired 19.9 percent of Sensus...
...company received the option to acquire the remainder of Sensus (see BioCentury, June 21, 1999). Sensus...
BioCentury | Apr 24, 2000
Clinical News

Somavert pegvisomant: Phase III

...Total symptoms and signs of acromegaly decreased significantly in all Somavert groups as well (p?0.05). Sensus...
BioCentury | Apr 19, 2000
Clinical News

Sensus publishes Somavert acromegaly data

Sensus (Austin, Texas) published in The New England Journal of Medicine results of its 112-patient Phase III trial that showed a significant reduction of IGF-I to normal levels, the primary end point, with all 3...
BioCentury | Apr 10, 2000
Company News

Sensus Drug Development Corp., Shearwater Polymers Inc. deal

...Sensus licensed Shearwater's polyethylene glycol (PEG) technology for the pegylation of Sensus' Somavert pegvisomant (formerly Trovert...
...19.9 percent of Sensus and has an option to acquire the rest of the company. Sensus...
BioCentury | Jun 21, 1999
Company News

Sensus Drug Development Corp., Pharmacia & Upjohn deal

...position. Sensus’ pegvisomant growth hormone receptor antagonist has completed Phase III testing to treat acromegaly. Sensus...
BioCentury | Jun 21, 1999
Clinical News

Pegvisomant: Phase III

...a normalization of IGF-I. Data were presented at the Endocrine Society meeting in San Diego. Sensus...
Items per page:
1 - 10 of 21
BioCentury | Oct 21, 2013
Company News

Osmotica Pharmaceutical management update

...Neurology, Drug delivery Hired: Kenneth Gayron as VP and CFO, formerly VP and treasurer at Sensus...
BioCentury | May 28, 2002
Company News

Tercica Medica Corp. management update

...Calif. Business: Metabolic Hired: John Scarlett as president, CEO and a director, formerly CEO of Sensus...
BioCentury | May 20, 2002
Company News

C Sixty management update

...Sixty Inc. , Houston, Texas Business: Chemistry Hired: Robert Davis as CEO, formerly EVP at Sensus...
BioCentury | Jul 23, 2001
Company News

Hyseq Inc. management update

...Pharmacogenetics Hired: William Bennett as SVP of research, formerly SVP of research and manufacturing at Sensus...
BioCentury | Mar 12, 2001
Company News

Sensus Drug Development Corp., Pharmacia deal

...option to acquire the 81.1 percent of Sensus it did not already own. Last month, Sensus...
...The product has Orphan Drug designation and priority review status. PHA acquired 19.9 percent of Sensus...
...company received the option to acquire the remainder of Sensus (see BioCentury, June 21, 1999). Sensus...
BioCentury | Apr 24, 2000
Clinical News

Somavert pegvisomant: Phase III

...Total symptoms and signs of acromegaly decreased significantly in all Somavert groups as well (p?0.05). Sensus...
BioCentury | Apr 19, 2000
Clinical News

Sensus publishes Somavert acromegaly data

Sensus (Austin, Texas) published in The New England Journal of Medicine results of its 112-patient Phase III trial that showed a significant reduction of IGF-I to normal levels, the primary end point, with all 3...
BioCentury | Apr 10, 2000
Company News

Sensus Drug Development Corp., Shearwater Polymers Inc. deal

...Sensus licensed Shearwater's polyethylene glycol (PEG) technology for the pegylation of Sensus' Somavert pegvisomant (formerly Trovert...
...19.9 percent of Sensus and has an option to acquire the rest of the company. Sensus...
BioCentury | Jun 21, 1999
Company News

Sensus Drug Development Corp., Pharmacia & Upjohn deal

...position. Sensus’ pegvisomant growth hormone receptor antagonist has completed Phase III testing to treat acromegaly. Sensus...
BioCentury | Jun 21, 1999
Clinical News

Pegvisomant: Phase III

...a normalization of IGF-I. Data were presented at the Endocrine Society meeting in San Diego. Sensus...
Items per page:
1 - 10 of 21